Barrera-Esparza María, Carreón-Torres Elizabeth, Jiménez-Osorio Angélica Saraí, Angel-García Julieta, Jiménez-Garza Octavio, Flores-Chávez Olga Rocío, Mendoza-Catalán Geu S, Estrada-Luna Diego
Coordinación de Unidades de Segundo Nivel, Oficina Central, Servicios de Salud del Instituto Mexicano del Seguro Social para el Bienestar (IMSS-BIENESTAR), Mexico City, Mexico.
Physics Institute, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.
Front Endocrinol (Lausanne). 2025 May 13;16:1578552. doi: 10.3389/fendo.2025.1578552. eCollection 2025.
Fatty acids disorders may lead to insulin resistance, resulting in long-term oxidative stress and inflammatory processes, both mediated by adipose tissue. Either in normal condition or obesogenic status, adipose cells components play an important role in several physiological and metabolic conditions. It has been shown that bioactive compounds can influence the development of obesity and its pathological complications such as insulin resistance. In this study, we performed a network between bioactive compounds and adipose tissue vis-a-vis insulin resistance. We constructed a regulatory network of 62 adipocyte cell components that incorporates current evidence of cellular and molecular interactions involved in healthy and obesity states. The network incorporated information about inflammation pathways and inhibition of insulin signaling; insulin signaling and GLUT 4 translocation; triglycerides production; ATP production; M2 macrophages recruitment; adipogenesis and lipolysis as well as mitochondrial biogenesis. Our mathematical model showed a discernment between the impact of various bioactive substances on the transitions from health to obesity and vice versa. We found that anthocyanins, punicalagin, oleanolic acid, and NRG4 proved to be critical nodes in the transition from obesity to the healthy state, due to their switch-on potential to up-regulate the complex network resulting in a beneficial transition.
Front Endocrinol (Lausanne). 2025-5-13
Adv Exp Med Biol. 2024
J Biol Chem. 2021
Adv Exp Med Biol. 2024
Mol Metab. 2020-10
Nutr Metab Cardiovasc Dis. 2009-2
Biochem Biophys Res Commun. 2021-9-10
Acta Physiol (Oxf). 2024-12
Adv Exp Med Biol. 2024
Mol Metab. 2024-10
J Pharmacokinet Pharmacodyn. 2024-12
Sci Adv. 2024-6-21